CV Therapeutics, Inc. announced that it has sent Solvay Pharmaceuticals, Inc. a notice of termination under the companies' co-promotion agreement for Aceon (perindopril erbumine) tablets. Over the next several weeks, CV Therapeutics will conclude its promotion of Aceon.

There are no financial commitments for either company related to the termination of the co-promotion agreement. CV Therapeutics does not expect to recognize further revenues from Aceon.

"We are excited to focus our promotional efforts on Ranexa, as we continue to see growing interest in the cardiology community," said Louis G. Lange, MD, PhD, chairman and CEO of CV Therapeutics.

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.